U.S. Aerospace & Defense Stock News

Teledyne Technologies (TDY) has drawn fresh attention after unveiling a Wideband Limiter aimed at protecting radar and electronic warfare systems from high power RF and directed energy threats, alongside a new unmanned drone collaboration. See our latest analysis for Teledyne Technologies. The recent run of product launches in electronic warfare, RF components and thermal imaging, together with a credit agreement tweak, comes against a strong 30 day share price return of 11.34% and a 1 year...

Recent performance snapshot Universal Health Services (UHS) has attracted investor attention after recent share price moves, with the stock showing mixed returns over the past week, month and past 3 months. Over the past day, the share price return was about 1.2% lower, while the past week shows a decline of roughly 12%. In contrast, returns for the month were close to flat, and the past 3 months reflect a decline of about 12%. See our latest analysis for Universal Health Services. Universal...

In the past quarter, monday.com reported annual recurring revenue of US$1.34 billion alongside gross margins near 89%, underscoring robust demand for its cloud-based work management platform. An interesting angle is the company’s roughly 30-month payback period on customer acquisition costs, which highlights how efficiently it converts marketing spend into durable subscription revenue. Next, we’ll examine how this rapid ARR expansion and efficient customer acquisition influence monday.com’s...

If you are wondering whether Brookfield Infrastructure Partners is still good value at around US$38.94, the key question is how its current price lines up with what the underlying business might be worth. The unit price has been relatively firm recently, with a 6.3% move over the last 30 days and a 13.5% return year to date, while the 1 year return sits at 35.5% and the 5 year return at 39.8%. These moves sit against an ongoing stream of news about global infrastructure demand, financing...

Cryoport FY 2025 earnings snapshot Cryoport (CYRX) has reported its FY 2025 fourth quarter with revenue of US$45.5 million and a basic EPS loss of US$0.21, alongside net income from continuing operations showing a loss of US$10.5 million. The company has seen quarterly revenue track between US$41.0 million and US$45.5 million across FY 2025, while basic EPS losses ranged from US$0.17 to US$0.23 per share, providing a clear picture of consistent top line scale but ongoing bottom line pressure...

Stevanato Group FY 2025 Earnings Snapshot Stevanato Group (NYSE:STVN) has put another solid quarter on the board for FY 2025, with Q3 revenue of €303.2 million and basic EPS of €0.13, alongside trailing twelve month EPS of €0.52 on €1.17 billion of revenue, capped by 22.6% earnings growth over the past year. The company has seen revenue move from €259.6 million in Q2 2024 to €303.2 million in Q3 2025, while quarterly EPS has ranged between €0.08 and €0.18 over that period, setting up a...

STAAR Surgical FY 2025 earnings snapshot STAAR Surgical (STAA) has wrapped up FY 2025 with Q4 revenue of US$57.8 million and a basic EPS loss of US$0.37, keeping the focus firmly on the path back to profitability. The company has seen quarterly revenue range from US$42.6 million to US$94.7 million since the start of 2024, while basic EPS has swung between a loss of US$1.10 and a profit of US$0.20. This sets up a mixed picture on margins that investors may view as an ongoing turnaround story...

XPeng (XPEV) just reported February 2026 deliveries of 15,256 vehicles, alongside plans to roll out new models and supply its second generation assisted driving solution to Volkswagen, giving investors fresh data points to reassess the stock. See our latest analysis for XPeng. At a share price of US$16.17, XPeng has seen a 1 day share price return of 1.89%. However, the 7 day and year to date share price returns of 11.06% and 20.85% declines suggest momentum has cooled. This comes even as the...

Cricut (CRCT) just wrapped up FY 2025 with fourth quarter revenue of US$203.6 million and basic EPS of US$0.04, alongside net income of US$7.8 million, setting the tone for how the full year is being read by the market. The company has seen quarterly revenue shift from US$209.3 million with EPS of US$0.06 in Q4 2024 to US$203.6 million with EPS of US$0.04 in Q4 2025. Trailing twelve month EPS sits at US$0.36 on revenue of US$708.8 million, and that mix of steady top line and improving...

Recent performance snapshot for Jazz Pharmaceuticals (JAZZ) Jazz Pharmaceuticals (JAZZ) has attracted attention after a period of mixed short term moves and stronger longer term returns, with the stock closing at $188.69 and showing positive figures across several multi year horizons. See our latest analysis for Jazz Pharmaceuticals. Recent moves have been choppy, with a 1 day share price return of 1.08% and a 7 day share price return showing a 4.14% decline. However, the 30 day share price...

Strata Critical Medical (SRTA) has reported its FY 2025 numbers, with Q4 revenue at US$66.8 million and a basic EPS loss of US$0.06. Trailing twelve month revenue came in at US$197.1 million with a full year basic EPS loss of US$0.24. Over recent quarters, the company has reported revenue in a range from US$36.1 million to US$66.8 million, while quarterly basic EPS losses have moved between US$0.04 and US$0.12. This keeps the focus on how efficiently it is converting sales into earnings. With...

In recent days, Bank of America reinstated coverage of Tesla, highlighting its leadership in consumer-focused autonomy, robotaxis operating in cities like Austin and San Francisco, and longer-term opportunities in Optimus humanoid robots and energy storage. This renewed analyst focus underscores how Tesla’s push to become a “physical AI” and software-led mobility platform is increasingly central to how investors view the business, beyond its core electric vehicle sales. We’ll now examine...

CareTrust REIT (CTRE) is back in focus after reporting earnings and revenue that exceeded analyst estimates, while also expanding its healthcare property footprint through acquisitions in the United States and the United Kingdom. See our latest analysis for CareTrust REIT. At a recent share price of US$39.29, CareTrust REIT has seen a 7.9% 1 month share price return and an 8.2% year to date share price return. Its 1 year total shareholder return of 54.3% and 3 year total shareholder return...

Texas Pacific Land (TPL) is back in focus after record Q4 and full year results, with rising oil and gas royalty volumes, strong water sales, insider buying, and fresh interest around power and data center projects. See our latest analysis for Texas Pacific Land. That backdrop of record results, data center and power opportunities, and steady insider buying has coincided with sharp momentum, with a 59.23% 1 month share price return and a 277.03% 5 year total shareholder return suggesting...

In late February 2026, UFP Technologies, Inc. extended and expanded its manufacturing supply agreement with Intuitive Surgical through December 31, 2029, while also reporting higher fourth-quarter and full-year 2025 sales and earnings compared with the prior year. This combination of a longer-term, higher-volume partnership with a key customer and recent earnings growth adds further visibility to UFP Technologies’ medical device exposure and contracted revenue base. Next, we’ll examine how...

In recent days, Huntington Bancshares has been in focus as analysts reassessed U.S. regional banks, highlighting expectations for resilient profits ahead of upcoming earnings. This wave of analyst attention, combined with a more constructive view on regional bank fundamentals, has reinforced Huntington’s positioning within the sector. Now we’ll explore how this renewed analyst confidence in regional banks, especially around profit resilience, could influence Huntington’s investment...

Praxis Precision Medicines (PRAX) recently reported fourth quarter and full year 2025 results, with net loss and loss per share from continuing operations higher than the prior year. This has put the company’s cash burn and pipeline priorities in sharper focus for investors. See our latest analysis for Praxis Precision Medicines. The stock has been volatile, with a 1 day share price return of 2.17% and a 90 day share price return of 71.14%. The 1 year total shareholder return is very large,...

National Vision Holdings (EYE) has put up a mixed FY 2025 scorecard so far, with Q3 revenue at US$487.3 million, basic EPS of US$0.04 and same store sales growth of 7.7%, set against a trailing twelve month loss of US$3.2 million and basic EPS of roughly US$0.04 loss. Over recent quarters the company has seen revenue range from US$451.7 million in Q2 2024 to US$510.3 million in Q1 2025. Basic EPS has moved from a Q4 2024 loss of US$0.37 per share to a Q1 2025 profit of US$0.18 per share and...

Avient stock in focus Avient (AVNT) is drawing fresh attention after recent share price moves, with the stock closing at $39.90. For investors, the latest returns across the month and past 3 months invite a closer look. See our latest analysis for Avient. Avient’s recent share price pullback over the past week sits against a stronger backdrop, with a 30 day share price return of 9.17% and a 90 day share price return of 28.96%. However, the 1 year total shareholder return of a 2.10% decline...

Accel Entertainment (ACEL) has wrapped up FY 2025 with fourth quarter revenue of US$341.4 million and EPS of US$0.19, capping a year in which trailing twelve month revenue reached US$1.3 billion and EPS came in at US$0.61. The company has seen quarterly revenue move from US$302.2 million in Q3 2024 to US$341.4 million in Q4 2025, while quarterly EPS stepped up from US$0.06 to US$0.19 over the same stretch, setting the backdrop for investors focused on earnings growth and profit consistency...

Brown Forman (BF.B) has just put out its Q3 2026 scorecard, with Q2 fiscal 2026 revenue of US$1.0 billion and basic EPS of US$0.47, supported by net income of US$224 million. Over recent quarters the company has seen revenue move from US$1.1 billion and EPS of US$0.55 in Q2 fiscal 2025 to US$1.0 billion and EPS of US$0.47 in Q2 fiscal 2026. Trailing 12 month EPS of about US$1.71 on revenue of US$3.9 billion gives investors a clearer read on the earnings run rate. Set against these headline...

GLOBALFOUNDRIES (GFS) has been in focus after its Q4 2025 earnings came in above the top end of management guidance, alongside a new multi billion dollar manufacturing partnership with Renesas Electronics. See our latest analysis for GLOBALFOUNDRIES. The strong Q4 report and Renesas partnership appear to have supported GLOBALFOUNDRIES’ recent momentum, with a 12.78% 1 month share price return contributing to a 26.58% 3 month gain and a 24.40% 1 year total shareholder return, even though the 3...

Why NBT Bancorp Is On Investor Radars Today NBT Bancorp (NBTB) has attracted fresh attention after a recent share price move, with the stock closing at $43.01. That reaction has investors reassessing the bank's valuation and return profile. See our latest analysis for NBT Bancorp. The latest uptick comes after a choppy spell, with a 7 day share price return of a 4.87% decline and a 30 day share price return of a 5.29% decline. The year to date share price return of 3.41% and the 3 year total...

On 3 March 2026, Benchmark reaffirmed its positive analyst rating on Aeluma, Inc., citing Nvidia’s recent optical investments as an important sector reference point for the company’s technology focus. This endorsement underscores how investor attention around Aeluma is increasingly tied to perceived alignment with larger industry players pursuing advanced optical solutions for AI infrastructure. We’ll now examine how Benchmark’s renewed confidence, anchored in Nvidia’s optical investment...